Canntab Therapeutics Limited (CSE:PILL) (OTCMKTS:CTABF) revealed Monday that Health Canada has granted it a cannabis research licence for continuing the research and development of its pharmaceutical-grade cannabis hard pill formulations at its Markham Ontario facility.
In a statement, the Canadian company said that after getting a standard processing licence and sale for medical purposes licence from Health Canada, Canntab will begin full-scale manufacturing of its suite of precision oral dose products.
The firm is a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application. The company's hard pill oral delivery formulations encapsulate extended-release, instant release, and bi-layered hard pills which offer patients and practitioners accurate dosing.
READ: Canntab Therapeutics submits Site Evidence Package to Health Canada for Licence Producer Status approval
The additional licences will enable Canntab to submit a notice of new cannabis products (NNCP) to Health Canada, said the company.
Jeff Renwick, co-founder and CEO of Canntab said the just granted cannabis research licence will allow the company to prepare for when it receives its standard processing licence and sale for medical purposes licence, which are likely to come through “shortly.”
“Once we obtain our Standard Processing Licence and Sale for Medical Purposes Licence, we will have products ready for distribution and sale,” said Renwick.
"Our facility is fully built-out and we are excited to prepare our final formulations for submission. We are equally excited with the prospect of continuing R&D in full force at our Markham facility, beginning with our proprietary oral dissolvable Tablet formulations which enter through the buccal cavity in the patient's mouth," he added.
Canntab’s facility, located in Markham, Ontario, is designed and fully equipped to accommodate all manufacturing necessary to produce Canntab's pharmaceutical-grade cannabis hard pill formulations (solid oral dosage forms), which the company believes is the future of medical cannabis.
Contact the author Uttara Choudhury at email@example.com
Follow her on Twitter: @UttaraProactive